SCPX · As filed with the SEC
Scorpius Holdings cash flow statement, by fiscal year
The statement as Scorpius Holdings presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Cash Flows from Operating Activities | ||||
| Net loss | (34,327,788) | (46,833,186) | (43,862,197) | (35,400,807) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | 7,154,149 | 6,474,256 | 2,115,015 | 607,667 |
| Noncash lease expense | — | — | — | 83,809 |
| Noncash interest expense | — | — | — | 21,970 |
| Noncash lease expense | 351,226 | — | — | — |
| Stock-based compensation | 1,033,718 | 2,628,276 | 4,085,737 | 6,168,981 |
| Unrealized gain on short-term investments | (999) | (123,019) | 1,701,443 | 842,538 |
| Deferred tax liability | — | (571,120) | (3,288,937) | (145,974) |
| Loss on disposal of equipment | 563,865 | — | — | — |
| Loss on extinguishment | 560,000 | — | — | — |
| Loss on impairment of long-lived assets | 1,939,246 | — | — | — |
| Change in fair value of related party receivable | 330,000 | — | — | — |
| Change in fair value of contingent earn-out receivable, related party | (1,190,000) | — | — | — |
| Change in fair value of convertible promissory notes, related party | (280,950) | — | — | — |
| Change in fair value of non-convertible promissory notes, related party | 19,000 | — | — | — |
| Change in fair value of warrant liability | (469,800) | — | (11,020) | (22,758) |
| Change in fair value of contingent consideration | — | — | — | 430,000 |
| Change in fair value of contingent consideration | — | — | (3,452,015) | — |
| Change in fair value of contingent consideration | — | (107,355) | — | — |
| Payment of contingent consideration | — | (1,073,145) | — | — |
| Goodwill impairment loss | — | 3,873,079 | — | 1,452,338 |
| Intangible asset impairment loss | — | 2,277,921 | — | — |
| Intangible asset impairment loss | — | — | 3,500,000 | 2,366,000 |
| Amortization of intangible asset | — | 1,091,250 | 1,030,625 | — |
| Noncash lease expense | — | 514,665 | 116,583 | — |
| Gain on sale of discontinued operations | — | (1,467,451) | — | — |
| (Increase) decrease in: | ||||
| Accounts receivable | 232,911 | (293,698) | (15,967) | 110,111 |
| Prepaid expenses and other current assets | (763,560) | 2,731,454 | 58,656 | (1,060,915) |
| Grant receivable | — | — | — | (1,318,359) |
| Other assets | — | — | — | (12,193,540) |
| Grant receivable | — | 1,524,522 | (206,163) | — |
| Contract receivables | — | — | 24,526,231 | — |
| Inventory | 710,470 | (909,158) | 5,844,000 | — |
| Other assets | — | (368,124) | — | — |
| Deposits | (20,334) | — | — | — |
| Income tax receivable | — | 600,877 | 443,968 | — |
| Right-of-use assets | — | (277,807) | (12,158,238) | — |
| Other assets | — | — | 12,233,529 | — |
| Deposits | — | 42,439 | (64,560) | — |
| Accounts payable | (882,427) | (116,908) | 3,299,326 | (126,937) |
| Deferred revenue | (923,347) | 771,133 | 1,583,308 | (806,217) |
| Accrued expenses and other liabilities | (42,021) | (1,921,496) | (3,126,158) | 929,023 |
| Other long-term liabilities | — | — | (53,530) | 17,286 |
| Deposits | — | — | — | (83,122) |
| Net Cash Used In Operating Activities | (26,006,641) | (31,532,595) | (5,700,364) | (38,128,906) |
| Cash Flows from Investing Activities | ||||
| Purchase of short-term investments | (935,639) | (483,497) | (2,457,348) | (66,960,279) |
| Proceeds from sale of short-term investments | 3,008,050 | 34,237,270 | 53,243,519 | 78,635,257 |
| Purchases of property and equipment | (875,155) | (1,985,557) | (20,117,998) | (1,904,713) |
| Proceeds from disposal of property and equipment | 16,914 | 220,802 | 388,103 | — |
| Proceeds from sale of Elusys Therapeutics | — | 247,577 | — | — |
| Acquisition of Elusys Therapeutics, net of cash paid | — | — | 2,719,899 | — |
| Payment of contingent consideration | — | — | (22,784,571) | — |
| Net Cash Provided by Investing Activities | 1,214,170 | 32,236,595 | 10,991,604 | 9,770,265 |
| Cash Flows from Financing Activities | ||||
| Proceeds from December 2024 Offering | 3,324,723 | — | — | — |
| Repayments of principal under finance lease | (898,774) | (2,583,583) | (231,633) | (183,010) |
| Proceeds from issuance of common stock | 22,006,353 | 65,624 | 59,692 | 26,304,282 |
| Proceeds from the exercise of stock options | — | — | — | 27,261 |
| Stock issuance costs | (2,219,463) | — | — | (658,184) |
| Proceeds from issuance of convertible promissory note, related party | 2,253,750 | — | — | — |
| Proceeds from issuance of non-convertible promissory notes, related party | 975,000 | — | — | — |
| Proceeds from issuance of common stock through at-the-market | 8,053 | — | — | — |
| Proceeds from issuance of common stock upon exercise of warrants | 178,392 | — | — | — |
| Proceeds from issuance of common stock under ESPP | 12,904 | — | — | — |
| Payment of contingent consideration | — | (6,434,115) | (4,735,000) | — |
| Cash paid for fractional shares in connection with reverse stock split | (4,582) | — | — | — |
| Net Cash Provided by (Used In) Financing Activities | 25,636,356 | (8,952,074) | (4,906,941) | 25,490,349 |
| Effect of exchange rate changes on cash and cash equivalents | — | — | — | (9,719) |
| Effect of exchange rate changes on cash and cash equivalents | (813) | (1,555) | (3,624) | — |
| Net Increase (Decrease) in Cash and Cash Equivalents | 843,072 | (8,249,629) | 380,675 | (2,878,011) |
| Cash and Cash Equivalents - Beginning of the Period | 184,925 | 8,434,554 | 8,053,879 | 10,931,890 |
| Cash and Cash Equivalents - End of the Period | 1,027,997 | 184,925 | 8,434,554 | 8,053,879 |
| Supplemental Disclosure for Cash Flow Information: | ||||
| Right-of-use assets surrendered upon operating lease modifications | (91,890) | — | — | — |
| Right-of-use assets obtained upon operating lease commencements | — | 895,578 | 6,348,346 | 88,596 |
| Right-of-use assets obtained on operating lease modifications | — | — | — | 37,767 |
| Right-of-use assets obtained upon finance lease commencements | — | 9,983,504 | 15,477,515 | 408,677 |
| Right-of-use assets surrendered upon financing lease modifications | — | (3,092,408) | — | — |
| Right-of-use assets obtained upon financing lease modifications | — | 70,033 | 37,654 | — |
| Right-of-use assets obtained upon operating lease modifications | — | 87,839 | (81,752) | — |
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Purchases of property and equipment included in accounts payable | — | — | 288,807 | — |
| Contingent and deferred cash consideration related to Elusys acquisition | — | — | 42,853,685 | — |
| Reclassification of contingent earn-out receivable, related party to related party receivable | 1,430,000 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.